Epstein-Barr virus neutralizing antibody levels and risk of multiple sclerosis

Multiple Sclerosis Journal

Volumn 18, Issue 8, 2012, Pages 1185-1187

  Simon, Kelly Claire ^a,b   O'Reilly, Eilis J ^a   Munger, Kassandra L ^a   Finerty, Susan ^c   Morgan, Andrew J ^c   Ascherio, Alberto ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Epstein Barr nuclear antigen; Epstein Barr virus; glycoprotein 350; infectious mononucleosis; multiple sclerosis; neutralizing antibodies

Indexed keywords

EPSTEIN BARR VIRUS NEUTRALIZING ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PROSPECTIVE STUDY; RISK FACTOR;

EID: 84864115800     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511433920     Document Type: Article

References (9)

1. Levin LI, Munger KL, O'Reilly EJ, Falk KI, Ascherio A. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol. 2010 ; 67: 824-830
2. Ascherio A, Munger KL. Epstein-Barr virus infection and multiple sclerosis: a review. J Neuroimmune Pharmacol. 2010 ; 5: 271-277
3. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: The role of infection. Ann Neurol. 2007 ; 61: 288-299
4. Morgan AJ, Khanna R Human Herpesviruses: Biology, Therapy and Immunoprophylaxis. Arvin AM Campadelli-Fumi G Mocarski E, ed. Cambridge: Cambridge University Press ; 2007 :
5. Nemerow GR, Mold C, Schwend VK, Tollefson V, Cooper NR. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J Virol. 1987 ; 61: 1416-1420
6. Sokal EM, Hoppenbrouwers K, Vandermeulen C, et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis. 2007 ; 196: 1749-1753
7. Lindsey JW, Hatfield LM, Vu T. Epstein-Barr virus neutralizing and early antigen antibodies in multiple sclerosis. Eur J Neurol. 2010 ; 17: 1263-1269
8. Ascherio A, Munger KL, Lennette ET, et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: A prospective study. JAMA. 2001 ; 286: 3083-3088
9. Wilson AD, Morgan AJ. Indirect measurement of Epstein-Barr virus neutralising antibodies by ELISA. J Virol Methods. 1998 ; 73: 11-19